Pyxis Oncology (PYXS) Stock Forecast & Price Target

Pyxis Oncology is attractive because MICVO is showing differentiated activity in a difficult 2L+ R/M HNSCC setting, with a 36% confirmed ORR, 94% disease control rate, and rapid, deep responses in a heavily pretreated population. The data also suggest a durable and broadly applicable profile, with similar efficacy in HPV-positive and HPV-unrelated disease, plus median PFS of 6.2 months and a 79% 12-month survival probability, which strengthens the case for a pivotal program. Importantly, dose capping appears to be improving tolerability by reducing treatment-related discontinuations versus the earlier cohort, supporting a better risk-reward profile and increasing confidence that the EDB+FN-targeted ADC strategy can scale beyond this indication.

Pyxis Oncology is facing a fundamentally fragile investment case because its lead asset still carries meaningful clinical and tolerability risk despite dose-capping improvements. Even at 5.4 mg/kg, 91.4% of patients had treatment-related adverse events, 40.0% needed dose reductions, and 14.3% discontinued due to treatment-related toxicity, while the company also recorded a $20.964 million impairment of in-process research and development intangible asset. Management also withheld the underlying above-cap figures and the stock remains exposed to clinical, regulatory, manufacturing, and dilution risks if MICVO fails to prove durable efficacy or commercial viability.